Brought to you by 
Lung Therapeutics closes $14.3mm Series B
07 Jun 2017
Executive Summary
Respiratory disease-focused Lung Therapeutics Inc. raised $14.3mm in its Series B financing led by Bios Partners, which was joined by returning shareholder the UT Horizon Fund. The company will use the funds for ongoing clinical trials in Australia and New Zealand of its LTI01 for empyema and complicated parapneumonic effusions, and for continued development of preclinical LTI03 for idiopathic pulmonary fibrosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lung Therapeutics closes $14.3mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice